MBQ-Pharma targets Rac and CDC42 as key targets for tumor growth inhibition and removal of pre-existing metastasis. MBQ-167 is a first-in-class nanomolar IC50 inhibitor for Rac and CDC42 and has been shown in mouse tumor models to inhibit tumor growth and to reverse advanced metastasis. MBQ-167 has also been shown to have no toxicity findings in rats and dogs through GLP studies and in Safety Pharmacology studies. The IND for MBQ-167 is scheduled by the end of 2021.
Company Details
- Employees
- 4
- Founded
- -
- Address
- 998 Avenida Luis Munoz Rivera, San Juan,puerto Rico 00927,puerto Rico
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- mbqpharma.com
- Keywords
- Oncology and Therapeutics.
- HQ
- San Juan, Puerto Rico
- Competitors
- Pietrantoni Mendez & Alvarez LLC, Cancer-EX, Cultimar Technologies, Centro Comprensivo de Cáncer de la Universidad de Puerto Rico / UPR Comprehensive Cancer Center, Carbono3, PRCCI Clinical Research Solutions, SwanBio LLC, FDI Clinical Research, ESCEND PHARMACEUTICALS, INC., Temple Therapeutics.
Mbq Pharma Questions
Mbq Pharma's website is mbqpharma.com
Mbq Pharma's LinkedIn profile is https://pr.linkedin.com/company/mbq-pharma
Mbq Pharma has
4 employees.
View email and phone details for 4
employees at Mbq Pharma.
Mbq Pharma's industry is
Pharmaceutical Manufacturing
Mbq Pharma's top competitors are
Pietrantoni Mendez & Alvarez Llc,
Cancer-Ex,
Cultimar Technologies,
Centro Comprensivo De Cáncer De La Universidad De Puerto Rico / Upr Comprehensive Cancer Center,
Carbono3,
Prcci Clinical Research Solutions,
Swanbio Llc,
Fdi Clinical Research,
Escend Pharmaceuticals, Inc.,
Temple Therapeutics.
Mbq Pharma's categories are Pharmaceutical Manufacturing
Mbq Pharma's founding year is 2018
